Autres langues TxCell

Actions

TXCL

FR0010127662

Temps réel Euronext Paris Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^EUR	-.--%		-.--%	+67,53 %

2018	TxCell : acquisition par Sangamo finalisée	CF
2018	TxCell : retrait obligatoire ce jeudi	CF

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

TxCell : Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares	01/10/18
TxCell : Sangamo Therapeutics to Acquire TxCell	23/07/18
TxCell : exercises in-license option to the University of British Columbia’s intellectual property rights of the HLA-A2 CAR-Treg program	09/07/18
TxCell : First in vivo proof-of-concept data with CD8+ CAR-Treg presented at FOCIS 2018	21/06/18
TxCell : to present its latest manufacturing process achievements at the 3rd Annual Bioprocessing of Advanced Cellular Therapies Congress	28/05/18
TxCell : 2016 financial results	06/04/17
TxCell : to hold conference call on Friday, March 10, 2017 following the publication of its 2016 financial results	06/04/17
TXCELL : September 2016 - TxCell to publish results for the first half of 2016 and to provide strategy update on Tuesday, September 27, 2016	26/09/16
TxCell : appoints Biogen’s Dr. Olivier Danos, pioneer in gene therapy for neurological disorders, to its Scientific Advisory Board	05/09/16
TxCell: financial information for the 2nd quarter of 2016	24/08/16
TxCell : to participate in leading scientific conferences in Q3 2016	27/07/16
TxCell : exercises option from Weizmann Institute of Science following effective grant of broad CAR-Treg patent in Europe	11/07/16
TxCell : implements a new financing contract of up to €20 million in nominal value through convertible notes with warrants (OCABSA)	21/06/16
TxCell : and the Lübeck Institute of Experimental Dermatology launch collaboration to develop CAR-Tregs in bullous pemphigoid	14/06/16
TxCell : presents a series of new scientific data at the ISCT 2016 Annual Meeting	01/06/16
TxCell und das Lübecker Institut für Experimentelle Dermatologie starten Kollaboration zur Entwicklung von CAR-Tregs im bullösen Pemphigoid	01/06/16
TxCell: financial information for the 1st quarter of 2016	25/04/16
TxCell : to participate in leading scientific conferences in Q2 2016	20/04/16
TxCell : appoints PCT as its US manufacturing partner	31/03/16
TxCell : 2015 results and update on strategy and outlook	15/03/16

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues TxCell

Actions

TXCL

FR0010127662

Autres langues

Filtres